Literature DB >> 8851613

Penetration of ciprofloxacin and fleroxacin into biliary tract.

C E Edmiston1, E C Suarez, A P Walker, M P Demeure, C T Frantzides, W J Schulte, S D Wilson.   

Abstract

Forty patients with chronic cholecystitis or cholelithiasis were prospectively randomized for therapy with either ciprofloxacin or fleroxacin to study the penetration of these two agents into gallbladder tissue, plasma, and bile. Patients received a 3-day course of ciprofloxacin (500 mg twice a day) or fleroxacin (400 mg once daily) and were subdivided into four groups reflecting intraoperative sample collection at 4, 7, 14, and 25 to 26 h following the last quinolone dose. Mean concentrations in plasma for ciprofloxacin and fleroxacin at 4 and 25 to 26 h postdose were 2.5 and 10 micrograms/ml and 0.3 and 1.8 micrograms/ml, respectively. The concentrations of ciprofloxacin and fleroxacin in bile and gallbladder wall tissue at 25 to 26 h postdose were 4.5 and 8.6 micrograms/ml and 1.2 and 4.4 micrograms/ml, respectively. Both agents demonstrate rapid tissue penetration with persistence at levels appropriate for treatment of biliary pathogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851613      PMCID: PMC163200     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Preoperative antibiotics in biliary surgery.

Authors:  S H Chetlin; D W Elliott
Journal:  Arch Surg       Date:  1973-08

2.  Antibiotic prophylaxis in gastric, biliary and colonic surgery.

Authors:  H H Stone; C A Hooper; L D Kolb; C E Geheber; E J Dawkins
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

3.  Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.

Authors:  J Barre; G Houin; J P Tillement
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

4.  Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.

Authors:  T C Gasser; S C Ebert; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

5.  Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.

Authors:  T Chang; A Black; A Dunky; R Wolf; A Sedman; J Latts; P G Welling
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

6.  Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration.

Authors:  M Dan; N Verbin; A Gorea; H Nagar; S A Berger
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.

Authors:  J M Brogard; F Jehl; H Monteil; M Adloff; J F Blickle; P Levy
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

9.  In-vitro activity of fleroxacin compared with three other quinolones.

Authors:  D A Bremner; A S Dickie; K P Singh
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

10.  Biliary tract excretion of ofloxacin in man.

Authors:  A Kazmierczak; A Pechinot; J M Duez; O Haas; J P Favre
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more
  2 in total

Review 1.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

2.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.